Chemaphor Inc. operates in the multi-billion dollar animal and human health markets. The company’s goal is to commercialize a range of product applications from its technology platforms with:

  • secured licensing agreements
  • collaborations and alliances with selected industry partners
  • the successful launch of pet products in the US and Canada
  • the strengthening of an already sound IP portfolio

Chemaphor's technologies are based on Natural Health Optimizers ("NHOs"). NHOs work with and support the natural systems that exist within the body to strive to maintain optimal health and function, e,g, by supporting immune function. Chemaphor’s major technology is Fully Oxidized Beta-Carotene (OxC-beta).

Chemaphor’s target NHO markets are:

  • Pet Wellness
  • Livestock Health & Productivity Enhancement
  • Human health and Wellness
  • Human health and Wellness

The OxC-beta platform addresses all three target markets.

Chemaphor is a publicly listed biotechnology company trading on the TSX Venture Exchange under the ticker "CFR". The company has two R&D operations located in the Industrial Partnership Facilities in NRC’s Steacie Institute for Molecular Sciences in Ottawa (Chemistry), and the Institute for Nutrisciences and Health in Charlottetown, Prince Edward Island (Nutriscience). Chemaphor is headquartered in Ottawa, Canada and was established August 4th, 2005.

© 2011 Chemaphor Inc. All rights reserved.